Abstract
416P Cost-effectiveness of first-line (1L) ribociclib use vs palbociclib in the treatment of postmenopausal women with HR+/HER2− advanced breast cancer (ABC): Analysis based on final overall survival (OS) results of MONALEESA-2 (ML-2) and PALOMA-2 (PAL-2)
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
